NYSE$MDT
Medtronic PLC · Q4 2021 earnings
Q4 2021 earnings · · Investor relations
Briefing
Medtronic's Q4 2021 financial results reflected a strong recovery with revenue increasing 37% as reported and 32% organically.
Medtronic reported a strong end to fiscal year 2021, with fourth quarter revenue of $8.188 billion, a 37% increase as reported and 32% organically. GAAP diluted EPS was $1.00, and non-GAAP diluted EPS was $1.50. The company announced a 9% dividend increase and issued FY22 guidance.
- Q4 Revenue of $8.2 Billion Increased 37% Reported and 32% Organic
- Q4 GAAP Diluted EPS of $1.00; Q4 Non-GAAP Diluted EPS of $1.50
- Quarterly Dividend Increased to $0.63, Annual $2.52 from Prior $2.32; 44th Consecutive Year of Dividend Increases
- Company Issues FY22 Guidance
Headline financials
Revenue & EPS history
Medtronic · Revenue · Quarterly
$8.19B
Revenue by segment
Medtronic · $8.19B total across 9 segments · Q4 2021
- Surgical & Endoscopy$1.54B+32.0%18.8%
- Cardiac Rhythm & Heart Failure$1.54B+63.7%18.8%
- Cranial & Spinal Technologies$1.19B+93.8%14.6%
- Acute Care & Monitoring$796M+3.9%9.7%
- Structural Heart & Aortic$744M—9.1%
- Specialty Therapies$654M+232.0%8.0%
- Diabetes$647M+13.5%7.9%
- Coronary & Peripheral Vascular$624M-10.5%7.6%
- Neuromodulation$449M—5.5%
Forward guidance
The company expects revenue growth in its fiscal year 2022 to approximate 9 percent on an organic basis. In fiscal year 2022, the company expects diluted non-GAAP EPS in the range of $5.60 to $5.75, including an estimated 10 to 15 cent positive impact from foreign currency based on current exchange rates.
Tailwinds
- Strong organic revenue growth driven by new product launches
- End market recovery from the impact of the pandemic
- Investing at the front end of major product launches, including surgical robotics and renal denervation, to fully realize their potential
- Planning for the largest increase in R&D spend in company’s history
- Capitalizing on a long list of opportunities
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2021
-0.1%
Avg return
Earnings day
+0.2%
Avg return
5 days after
-1.4%
Avg return
30 days after
58%
38 / 66 earnings
Positive
+6.2%
Q1 2019
Best reaction
-7.3%
Q3 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +5.3% | +9.4% | — | |
| Q3 2026 | -2.8% | -2.6% | -12.7% | |
| Q2 2026 | +3.9% | +5.1% | +2.3% | |
| Q1 2026 | -3.1% | -0.1% | +3.0% | |
| Q4 2025 | -2.2% | -6.6% | -0.0% | |
| Q3 2025 | -7.3% | -3.1% | -1.7% | |
| Q2 2025 | -4.0% | -1.6% | -8.7% | |
| Q1 2025 | +3.2% | +4.2% | +5.5% | |
| Q4 2024 | -4.0% | -4.4% | -4.8% | |
| Q3 2024 | +1.8% | +1.5% | -1.2% | |
| Q2 2024 | +4.3% | +5.1% | +9.0% | |
| Q1 2024 | +2.5% | +0.7% | -1.4% | |
| Q4 2023 | -6.9% | -5.7% | -0.0% | |
| Q3 2023 | +0.4% | -1.5% | -8.5% | |
| Q2 2023 | -4.0% | -3.9% | -6.3% | |
| Q1 2023 | -4.1% | -3.9% | -10.2% | |
| Q4 2022 | -6.1% | -5.1% | -14.5% | |
| Q3 2022 | +2.4% | +5.2% | +5.7% | |
| Q2 2022 | -2.1% | -5.0% | -12.0% | |
| Q1 2022 | +4.7% | +4.1% | +1.7% | |
| Q4 2021 | +0.3% | -0.8% | +2.8% | |
| Q3 2021 | +2.6% | +1.1% | +0.7% | |
| Q2 2021 | +2.1% | +3.3% | +2.8% | |
| Q1 2021 | +3.9% | +7.7% | +1.1% | |
| Q4 2020 | -3.4% | -0.9% | -4.3% | |
| Q3 2020 | -3.0% | -3.5% | -32.5% | |
| Q2 2020 | +0.5% | -0.4% | +2.0% | |
| Q1 2020 | +3.5% | +1.8% | +6.6% | |
| Q4 2019 | +4.8% | +2.9% | +12.0% | |
| Q3 2019 | +0.6% | +1.6% | -0.2% | |
| Q2 2019 | +2.9% | +1.8% | -0.5% | |
| Q1 2019 | +6.2% | +6.1% | +8.3% | |
| Q4 2018 | +1.2% | +0.2% | +1.8% | |
| Q3 2018 | -3.1% | -3.5% | -6.2% | |
| Q2 2018 | +4.4% | +5.5% | +3.3% | |
| Q1 2018 | -4.5% | -5.3% | -4.8% | |
| Q4 2017 | +0.5% | +0.2% | +5.3% | |
| Q3 2017 | +0.9% | +2.7% | +2.5% | |
| Q2 2017 | -6.0% | -6.3% | -11.0% | |
| Q1 2017 | -0.1% | +0.2% | +1.2% | |
| Q4 2016 | -1.4% | +1.5% | +6.2% | |
| Q3 2016 | -3.6% | — | — | |
| Q2 2016 | +2.7% | — | — | |
| Q1 2016 | -3.6% | — | — | |
| Q4 2015 | +0.2% | — | — | |
| Q3 2015 | +4.3% | — | — | |
| Q2 2015 | +3.7% | — | — | |
| Q1 2015 | +1.1% | — | — | |
| Q4 2014 | -1.0% | — | — | |
| Q3 2014 | -1.2% | — | — | |
| Q2 2014 | -2.4% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +3.3% | — | — | |
| Q3 2013 | -5.0% | — | — | |
| Q2 2013 | +1.6% | — | — | |
| Q1 2013 | +1.2% | — | — | |
| Q4 2012 | +2.1% | — | — | |
| Q3 2012 | +2.0% | — | — | |
| Q2 2012 | -6.5% | — | — | |
| Q1 2012 | -3.2% | — | — | |
| Q4 2011 | +1.5% | — | — | |
| Q3 2011 | +1.4% | — | — | |
| Q2 2010 | -0.2% | — | — | |
| Q1 2010 | +1.5% | — | — | |
| Q4 2010 | +0.7% | — | — | |
| Q3 2009 | +0.6% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro